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Background and Purpose: L-DOPA-induced dyskinesia (LID) is considered a major
complication in the treatment of Parkinson's disease (PD). Buspirone (5-HT1A partial
agonist) have shown promising results in the treatment of PD and LID, however no
5-HT-based treatment has been approved in PD. The present study was aimed to
investigate how the substantia nigra pars reticulata (SNr) is affected by buspirone and
whether it is a good target to study 5-HT antidyskinetic treatments.
Experimental Approach: Buspirone was studied using in vivo single-unit, electrocorti-
cogram, local field potential recordings along with microdialysis and immunohisto-
chemistry in naïve/sham, 6-hydroxydopamine (6-OHDA)-lesioned or 6-OHDA-
lesioned and L-DOPA-treated (6-OHDA/L-DOPA) rats.
Key Results: Local buspirone inhibited SNr neuron activity in all groups. However,
systemic buspirone reduced burst activity in 6-OHDA-lesioned rats (with or without
L-DOPA treatment), whereas 8-OH-DPAT, a full 5-HT1A agonist induced larger inhib-
itory effects in sham animals. Neither buspirone nor 8-OH-DPAT markedly modified
the low-frequency oscillatory activity in the SNr or synchronization within the SNr
with the cortex. In addition, local perfusion of buspirone increased GABA and gluta-
mate release in the SNr of naïve and 6-OHDA-lesioned rats but no effect in
6-OHDA/L-DOPA rats. In the 6-OHDA/L-DOPA group, increased 5-HT transporter
and decreased 5-HT1A receptor expression was found.
Conclusions and Implications: The effects of buspirone in SNr are influenced by
dopamine loss and L-DOPA treatment. The present results suggest that the regula-
tion of burst activity of the SNr induced by DA loss may be a good target to test new
drugs for the treatment of PD and LID.
Abbreviations: 6-OHDA, 6-hydroxydopamine; AIMs, Abnormal involuntary movements; ALO, axial, limb, and orolingual; CV, Coefficient of variation; DA, dopamine; ECoG, Electrocorticogram;
Glu, glutamate; LFP, Local field potential; LID, L-DOPA-induced dyskinesia; PD, Parkinson's disease; SERT, 5-HT transporter; SNr, Substantia nigra pars reticulata; 5-HT, Serotonin.
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1 | INTRODUCTION
Parkinson's disease (PD) pathophysiology involves the progressive loss of
different peripheral and central neuronal populations. Degeneration of
dopaminergic neurons of the substantia nigra pars compacta, leading to a
decrease in striatal dopamine (DA) levels, underlies the appearance of
motor deficits (Kish, Shannak, & Hornykiewicz, 1988). The current treat-
ment of Parkinson's disease motor symptoms focuses on restoring dopa-
minergic neurotransmission using the DA precursor L-DOPA,
dopaminergic receptor agonists and DA metabolism inhibitors. L-DOPA
provides the greatest symptomatic benefit, although its prolonged use is
associated with motor complications and decreased efficacy
(Olanow, 2008). The appearance of abnormal involuntary movements,
known as L-DOPA-induced dyskinesia (LID), complicates the manage-
ment of motor symptoms and, in some cases, can greatly affect patient
quality of life. Only amantadine (an N-methyl-D-aspartate (NMDA)
receptor antagonist) is currently marketed as antidyskinetic, but it lacks
long-term efficacy (Perez-Lloret & Rascol, 2018).
Many drugs acting on 5-HT receptors, such as 5-HT1A agonists,
5-HT1A/B agonists, 5-HT2A antagonists or 5-HT transporter (SERT) inhibi-
tors have been tested and proven to be effective in reducing L-DOPA-
induced dyskinesia in animal models (Bibbiani, Oh, & Chase, 2001; Bishop
et al., 2012; Grégoire et al., 2009; Hamadjida et al., 2018; Lindgren,
Andersson, Lagerkvist, Nissbrandt, & Cenci, 2010). However, no 5-HT-
based therapy has been approved for clinical use. The main problem is
that, regardless of the preclinical anti-dyskinetic evidence, none of these
drugs have achieved good enough results in clinical trials.
In spite of this lack of clinically efficacy of 5-HT drugs, several data
support the therapeutic relevance of the 5-HT system in L-DOPA-
induced dyskinesia as, for example, the fact L-DOPA is taken up, metabo-
lized to dopamine and released from 5-HT nerve terminals (for review,
see Miguelez, Benazzouz, Ugedo, & De Deurwaerdère, 2017; Politis
et al., 2014). Furthermore, results from studies in patients with
Parkinson's disease show a correlation between 5-HT1A/SERT binding
sites and tremors (Caretti et al., 2008; Doder, Rabiner, Turjanski, Lees, &
Brooks, 2003; Loane et al., 2013; Qamhawi et al., 2015) as well as a rela-
tionship between post-mortem SERT binding and dyskinesia-free survival
time (Rylander et al., 2010).
When investigating the possible effect of antidyskinetic drugs, it
is important to take into account the results collected in animal
models of Parkinson's disease that reveal the structural and functional
changes in the 5-HT system induced by DA depletion and/or chronic
administration of L-DOPA (see review Vegas-Suarez et al., 2019). In
this regard, we have observed that buspirone, a 5-HT1A receptor par-
tial agonist, inhibits neuronal activity in the subthalamic nucleus in
control rats but has no effect after DA depletion (Sagarduy
et al., 2016). Another study found that it efficiently improves the
behavioural score and reduces certain molecular changes associated
with L-DOPA-induced dyskinesia (Azkona et al., 2014). In addition, DA
depletion and/or chronic administration of L-DOPA have been associ-
ated with dysfunctional neuronal activity in several brain structures
among which is the substantia nigra reticulata (SNr) (Aristieta, Ruiz-
Ortega, Miguelez, Morera-Herreras, & Ugedo, 2016; Tseng, Riquelme,
Belforte, Pazo, & Murer, 2000). The SNr, one of the main basal ganglia
output nuclei, is densely innervated by 5-HT nerve fibres and contains
5-HT and 5-HT1A receptors (see Di Matteo et al., 2008). Furthermore,
electrical stimulation targeting the SNr alleviates some Parkinson's
disease symptoms (Collomb-Clerc & Welter, 2015; Hidding
et al., 2019; Weiss et al., 2013), while striatonigral optostimulation
induces dyskinesia in mice (Keifman et al., 2019).
The present study aimed at defining whether the SNr is involved
in the effects of buspirone and that it might be a good target to inves-
tigate antidyskinetic drugs. For this purpose, electrophysiological,
immunohistochemical and neurochemical approaches were applied in
6-hydroxydopamine (6-OHDA)-lesioned rats with and without pro-
longed treatment with L-DOPA.
2 | METHODS
2.1 | Animals
Animal studies are reported in compliance with the ARRIVE guidelines
(Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010) and with the
recommendations made by the British Journal of Pharmacology. For
electrophysiological and immunohistochemical experiments, male
Sprague–Dawley rats (SGIker facilities, University of the Basque
Country, UPV/EHU, Spain) weighing 150–175 g at the beginning of
the experiments were housed in groups of at least four animals under
standard laboratory conditions (22 ± 1C, 55 ± 5% relative humidity
and a 12:12-h light/dark cycle) with ad libitum access to food and
What is already known
• Buspirone is effective in reducing L-DOPA-induced dyski-
nesia (LID).
• Neuronal activity and low-frequency oscillatory activity
are increased in the SNr of 6-hydroxydopamine
(6-OHDA)-lesioned rats.
What this study adds
• Buspirone reduces SNr-burst activity and amino acid
release more markedly after dopamine (DA) loss.
• Expression of 5-HT1A receptors is reduced and 5-HT
transporter is enhanced in 6-OHDA/L-DOPA rats
What is the clinical significance
• The findings shed light on the mechanism of action of
buspirone in parkinsonism and LID.
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water. Experiments involving animals were approved by the Local Eth-
ical Committee of the University of Basque Country (UPV/EHU,
CEEA/M20/2016/176) following European (2010/63/UE) and Span-
ish (RD 53/2013) regulations for the care and use of laboratory
animals.
Microdialysis experiments were performed using male Sprague–
Dawley rats (150 g; Charles River, Calco, Lecco, Italy) following proto-
cols approved by the Ethical Committee of the University of Ferrara
and the Italian Ministry of Health (license no. 714/2016-PR). Every
effort was made to minimize animal suffering and to use the minimum
number of animals per group and experiment.
2.2 | Experimental design
Experiments were performed and results were analysed under blinded
conditions according to British Journal of Pharmacology (Kilkenny
et al., 2010). A total of 105 rats were used in this study (six rats were
excluded for technical reasons). Animals were divided into three
groups which are referred to as sham/naïve, 6-OHDA and 6-OHDA/
L-DOPA groups. Animals were randomly assigned to each group and
treatment. Only male animals were used, in order to avoid sex variabil-
ity. Initially, all groups had equal size, but after behavioural test or
immunohistochemistry verification of dopamine loss, results from six
animals were excluded. The size of each group for every study design
was determined by considering the accuracy and reproducibility of
methods used according to our previous published work. Figure 1
shows the timeline and the number of animals (in brackets) used in
each experiment. For electrophysiology recordings (experiment 1) and
for 5-HT1A and SERT immunostaining (experiment 3), rats received
6-OHDA or vehicle injections into the medial forebrain bundle and
the severity of the dopaminergic lesion was screened using the cylin-
der test at least 2 weeks later. L-DOPA was then administered daily
for 3 weeks and abnormal involuntary movements (AIMs) were evalu-
ated at baseline and on the 21st day. Electrophysiological recordings
or perfusion were performed at least 3 weeks after the lesion (sham
or 6-OHDA group) or 24 h after the last dose of L-DOPA (6-OHDA/L-
DOPA-treated group). At the end of the electrophysiological experi-
ments, animals were deeply anaesthetized (1.2 gkg−1 urethane, i.p.),
perfused with saline followed by 4% ice-cold paraformaldehyde pre-
pared in 0.1-M phosphate buffer and brains removed for histological
verification. For microdialysis experiments (experiment 2), rats
received 6-OHDA injections and were screened using the bar and
drag tests 3 weeks later. L-DOPA was administered for 3 weeks and
abnormal involuntary movements were evaluated. At least 3 weeks
after the lesion or 24 h after last L-DOPA injection, rats were
implanted with microdialysis probes. Each animal underwent two
microdialysis sessions (24 and 48 h after surgery) and received Ringer
solution or buspirone administration in a randomized fashion. Samples
were collected every 20 min for a total of 4 h. At the end of the
experiment the animals were killed by isoflurane overdose and the
brains removed and stored at −80C. Coronal sections (40 μm) were
cut using a cryostat LEICA microtome and the correct placement of
the microdialysis probe within the SNr was verified.
F IGURE 1 Schematic representation of the experimental design. At the beginning of the three experiments, animals received a vehicle or
6-OHDA injection into the right medial forebrain bundle. Three weeks later, dopaminergic depletion was evaluated by different asymmetry tests
(cylinder or bar and drag test). After that, rats received a 21-day treatment of daily L-DOPA injections (6 plus 12 mgkg−1 benserazide). Abnormal
involuntary movements (AIMs) were scored at baseline and at the end of the treatment. In experiments 1 and 2, electrophysiological recordings
and microdialysis assays in the SNr were performed after the L-DOPA chronic treatment. Finally, animals were perfused transcardially and
processed for histological examination. In experiment 3, sacrifice and tissue processing was performed after chronic treatment. *The group was
divided into three subgroups with the respective sizes indicated by bold numbers. TH, tyrosine hydroxlase
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2.3 | 6-OHDA lesions
6-OHDA lesions were performed according to our established proto-
cols (Aristieta et al., 2016). Thirty minutes before surgery, rats were
pretreated using desipramine (25 mgkg−1, i.p.) and pargyline
(50 mgkg−1, i.p.) in order to preserve the noradrenergic system and
the degradation of the toxin, respectively. Then rats were deeply
anaesthetized using isoflurane (1.5–2%, Esteve) and placed in the ste-
reotaxic frame (David Kopf® Instruments). 6-OHDA (3.5 μgμl−1, in
0.02% ascorbic acid) or vehicle was injected using a 10-μl Hamilton
syringe at a rate of 1 μlmin−1. A total of 7.5 and 6 μl, respectively,
was injected at two sites in the right medial forebrain bundle—2.5 μl
at anteroposterior (AP): −4.4 mm, mediolateral (ML): +1.2 mm and
dorsoventral (DV): −7.8 mm relative to bregma and dura with the
toothbar set at −2.4 and 2 μl at AP: −4.0 mm, ML: +0.8 mm and DV:
−8 mm with toothbar at +3.4 (Paxinos & Watson, 1997). The parkin-
sonian animals used in experiment 2 (see Figure 1) were lesioned fol-
lowing the same procedure with slight modifications according to
Arcuri et al. (2018).
2.4 | Behavioural tests
2.4.1 | Cylinder test
At least 2 weeks after the 6-OHDA lesion, forelimb asymmetry was
evaluated using the cylinder test as described previously (Miguelez,
Aristieta, Cenci, & Ugedo, 2011). Rats were placed in a transparent
glass cylinder (20 cm of diameter) with two mirrors positioned at a
90 angle behind the cylinder to allow a complete view of the explor-
atory activity. Each animal was left in place, freely exploring, until it
made at least 20 weight-bearing contacts on the glass walls using
either forelimb (maximal exploration time of 5 min). The percentage of
contralateral forelimb use with respect to the total number of con-
tacts was calculated. Only animals with an ipsilateral contact percent-
age ≥80% were enrolled in the experiments 1 or 3.
2.4.2 | Bar test
Three weeks after the 6-OHDA lesion, the bar test was performed as
previously described (Arcuri et al., 2018). The ipsilateral and contralat-
eral forelimbs were alternatively placed on three blocks of increasing
heights (3, 6 and 9 cm). The immobility time (in seconds) of each fore-
limb on the blocks was recorded for each step. Only animals that
reached a 20-s immobility time with the contralateral forelimb were
included in experiment 2.
2.4.3 | Drag test
Three weeks after the 6-OHDA lesion, the drag test was performed
(Arcuri et al., 2018). Briefly, each rat was lifted from the abdomen,
leaving each forelimb on the table and dragged backwards along a
fixed distance of 1 m at a constant speed of 20 cms−1. Two different
observers counted the number of contacts made by each forelimb.
Animals with a percentage of ipsilateral contacts with respect to total
contacts ≥80% were included in experiment 2.
2.4.4 | Long-term L-DOPA treatment and abnormal
involuntary movements rating
Abnormal involuntary movements were induced in 6-OHDA-lesioned
rats by daily injections of L-DOPA (6 mgkg−1, i.p.) in combination with
the peripheral decarboxylase inhibitor benserazide (12 mgkg−1, i.p.)
over 3 weeks (Aristieta et al., 2016; Aristieta, Ruiz-Ortega, Morera-
Herreras, Miguelez, & Ugedo, 2019; Azkona et al., 2014; Dekundy,
Lundblad, Danysz, & Cenci, 2007). Abnormal involuntary movements
were scored according to the scale described by Cenci and
Lundblad (2007). On the testing days, rats were placed individually in
transparent empty plastic cages for at least 10 min before drug admin-
istration. Each rat was observed for one full minute every 20th minute
along the 200-min testing period. The severity of the three subtypes
of dyskinetic movements (axial, limb and orolingual [ALO]) were rated
from 0 to 4 based on the amount of time for which the abnormal
movement was observed (i.e. 0, not present to 4, continuous). In addi-
tion, the amplitude of ALO abnormal involuntary movements were
rated on a scale from 0 to 4 separately from locomotive abnormal
involuntary movements. Data are expressed as the abnormal involun-
tary movements score/session for ALO, which were calculated by
multiplying the severity score by the amplitude scores during the
monitoring period, with all of these products summed for each testing
session (Lindgren et al., 2010). All 6-OHDA L-DOPA rats developed
severe dyskinetic movements that peaked between 40 and 100 min
after a single injection of L-DOPA and had a total score >100 on the
21st treatment day (Figure S1).
2.5 | Electrophysiological procedures
The electrophysiological recordings of SNr neurons were performed
at least 3 weeks after 6-OHDA or vehicle injection for the sham or
6-OHDA group or 24 h after the last L-DOPA injection in the
6-OHDA L-DOPA group (Aristieta et al., 2016). Rats were
anaesthetized using urethane (1.2 gkg−1, i.p.) and the right jugular
vein was cannulated for systemic drug administration. Next, each rat
was placed in a stereotaxic frame with its head secured in a horizontal
orientation. The rats were allowed to breath spontaneously. The
recording electrode was lowered into the right SNr (relative to bregma
and dura, AP: −5.3 mm, ML: −2.5 mm, DV: −7.5 to 8.5 mm)
(Paxinos & Watson, 1997). Neuronal spikes were digitized using the
CED micro 1401 interface and Spike2 software (Cambridge Electronic
Design). The basal firing rate was recorded for 300 s and at least
150 s after each systemic drug dose. For local administration, a cali-
brated pipette glued adjacent to a recording micropipette was filled
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with buspirone 0.25 M dissolved in Dulbecco's buffered saline solu-
tion (NaCl 136.9 mM; KCl 2.7 mM; NaH2PO4 8.1 mM; KH2PO4
1.5 mM; MgCl2 0.5 mM; and CaCl2 0.9 mM, pH 7.4) as previously per-
formed by Sagarduy et al. (2016). Local buspirone injection in the SNr
was applied with pressure pulses (50–150 ms) using a Picospritzer™ II
(General Valve Corporation, Fairfield, NJ, USA). The injected volume
was simultaneously monitored with soft movements in a calibrated
pipette in which each pulse corresponded to the injection of 2 nl of
solution. Several ejection pulses were applied in each application. The
effect of each dose on firing rate was recorded until the neuron
recovered. At the end of the experiments, a 5-μA cathodal current
was passed through the recording electrode to deposit a discrete
mark of Pontamine Sky on the recording site.
The electrocorticogram (ECoG) was simultaneously recorded via a
1-mm-diameter steel screw, which was juxtaposed to the dura mater
above the right frontal somatic sensory-motor cortex (AP: +4.5 mm
and ML: −2.5 mm to bregma) (Paxinos & Watson, 1997) as described
by Aristieta et al. (2016). The signal was pre-amplified (10×), amplified
(200×) and bandpass filtered (0.1–1000 Hz) in an amplifier (Cibertec
S.A., model amplifier 63AC). The discriminated electrocorticogram
activity (sampled at 2500 Hz) was digitized, stored and analysed using
computer software. The local field potential (LFP) in the SNr was
recorded through the same glass electrodes that were used for single-
unit extracellular recordings. The signal was pre-amplified (10×) and
then amplified (10×) in a high-input impedance amplifier (Cibertec
S.A., model amplifier AE-2) where the signal was also bandpass fil-
tered (0.1–5000 Hz). This signal was divided into two different signals
in a second amplifier (Cibertec S.A., model amplifier 63AC), namely,
the single-unit extracellular signal and the local field potential signal.
In this second amplifier, the local field potential signal was amplified
(10×) and bandpass filtered (0.1–100 Hz). The discriminated local field
potential activity (sampled at 2500 Hz) was digitized, stored and
analysed using computer software.
2.5.1 | Analysis of electrophysiological data
All electrophysiological parameters were analysed off-line using the
Spike2 software (version 7). Firing patterns were determined by ana-
lysing the interspike interval histogram:- firing rate and the coefficient
of variation (CV), which represents the measure of firing regularity
and is defined as the percentage ratio of the SD to the mean interval
histogram, which is obtained applying a Spike2 script (“meanix.s2s”).
The percentage of neurons exhibiting burst firing pattern from the
total and the burst-related parameters: the number of bursts (total
number of burst detected in the spike train), mean duration of burst
(mean duration of the total burst detected in the spike train and
expressed in ms), spikes per burst (mean of number of burst detected),
recurrence of burst (number of burst per min) and intraburst fre-
quency (mean of the interval of spike patterns within burst) were
analysed during a period of 90 s applying a Spike2 script (“surprise.
s2s”) based on Poisson Surprise method. For oscillatory activity and
synchronization parameters analysis, local field potential and
electrocorticogram signals (sampled at 2500 Hz) were smoothed to
1 ms and SNr action potentials were converted to a series of events
(sampled at 2500 Hz). These series of events were then transformed
to a continuous waveform (1-ms smoothing period) using a custom-
made Spike2 software script. The power spectrum of smoothed local
field potentials, electrocorticograms and SNr spike waveforms and the
coherence analyses between SNr spike waveforms and local field
potentials, SNr spike waveforms and electrocorticograms, and SNr-
local field potential and electrocorticograms were also analysed using
the fast Fourier transform (8,192 blocks size) in the low-frequency
range (0–5 Hz) from 90 s of data applying a Spike2 script (“coherac90.
s2s”). The significance of the coherence was determined by the equa-
tion described by Rosenberg, Amjad, Breeze, Brillinger, and
Halliday (1989): 1 − (1 − α)1/(L − 1), where α is 0.95 and L is the num-
ber of windows used. The AUC of coherence and power spectrum
curves were calculated in the 0- to 5-Hz low-frequency range.
2.6 | Probe implantation and in vivo microdialysis
procedures
Naïve, 6-OHDA and 6-OHDA/L-DOPA rats were stereotaxically
implanted with one microdialysis probe in the right SNr under iso-
flurane anaesthesia (Morari, O'Connor, Ungerstedt, Bianchi, &
Fuxe, 1996) according to the following coordinates relative to bregma
and dura—AP: −5.5 mm, ML: −2.2 mm and DV: −8.7 mm (Paxinos &
Watson, 1997). Concentric microdialysis probes were constructed
using AN69 (Gambro Industries, Meyzieu, France) semipermeable hol-
low membranes (65-kDa MW cut-off 340-μm outer diameter with an
active surface of 1.0 mm). Twenty-four hours after surgery, the
experimet was performed in conscious-freely moving rats. Probes
were thoroughly flushed (3.0 μlmin−1) with a modified Ringer solution
(CaCl2 1.2 mmolL−1, KCl 2.7 mmolL−1, NaCl 148 mmolL−1 and
MgCl2 0.85 mmolL−1). After 6 h of rinsing, four baseline samples were
collected (every 15 min) and buspirone was perfused at three increas-
ing concentration levels (50, 150 and 500 nM) for 1 h at each concen-
tration. A second microdialysis session was repeated 48 h after
surgery. Rats were randomized to Ringer/Ringer or Ringer/buspirone
in the first session and then treatment was crossed in the following
session.
2.6.1 | Analysis of endogenous GABA and
Glutamate
Glutamate (Glu) and GABA were measured using HPLC coupled with
fluorometric detection as previously described (Bido, Marti, &
Morari, 2011). Thirty microlitres of o-
phthaldialdehyde/mercaptoethanol reagent was added to 30-μl ali-
quots of sample and 50 μl of the mixture was automatically injected
(Triathlon autosampler; Spark Holland, Emmen, Netherlands) onto a
5-C18 Hypersil ODS analytical column (3-mm inner diameter, 10-cm
length; Thermo Fisher Scientific, Waltham, MA) perfused at a flow
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rate of 0.48 mlmin−1 (Jasco PU-2089 Plus quaternary pump; Jasco,
Tokyo, Japan) with a mobile phase containing 0.1-M sodium acetate,
10% methanol and 2.2% tetrahydrofuran (adjusted to pH 6.5 with gla-
cial acetic 99%). Glutamate and GABA were detected by means of a
fluorescence spectrophotometer (FP-2020 Plus; Jasco, Tokyo, Japan)
managed by the ChromNAV 2.0 HPLC software (Jasco, MD, USA).
The excitation and the emission wavelengths were set at 370 and
450 nm, respectively. Under these conditions, the limits of detection
for glutamate and GABA were 1 nM (i.e., 147 pgml−1) and
0.5 nM (i.e., 51 pgml−1) and maximum sensitivity was 10 μM for
both amino acids. The retention times were between 2.8 and 4 min
and between 16 and 19 min for glutamate and GABA, respectively.
2.7 | Histological procedures and analysis
Animals were deeply anaesthetized (1.2 gkg−1 urethane i.p.) and
transcardially perfused with saline followed by 4% ice-cold parafor-
maldehyde and 0.2% picric acid prepared in 0.1-M phosphate saline
buffer. Brains were removed and the following day they were trans-
ferred to a 25% sucrose solution until they sank. The brains were seri-
ally cut in coronal 40-μm sections using a freezing microtome and
slices were conserved in a cryoprotectant solution at −20C until fur-
ther processing.
2.7.1 | Immunohistochemistry
The Immuno-related procedures used comply with the recommenda-
tions made by the British Journal of Pharmacology (Alexander
et al., 2018). For tyrosine hydroxylase (TH) immunochemistry, sections
containing the striatum and the SNc were washed in potassium PBS
(KPBS; 0.02 M, pH 7.4). Then endogenous peroxidase was quenched
using 3% H2O2 and 10% (v/v) methanol in KPBS for 30 min at 22C.
After rinsing in KPBS, brain sections were preincubated in 1% Triton
X-100 with KPBS (KPBS-T) and 5% normal goat serum for 1 h at 22C
and then incubated with primary antibody (rabbit anti-TH, AB152,
1:1,000, Merck Millipore, Spain) overnight at 22C. Afterwards, the
sections were incubated with secondary antibody (biotinylated goat
anti-rabbit IgG, BA-1000, 1:200, Vector Laboratories, California, USA)
in KPBS-T with 2.5% NGS for 2 h at RT. All sections were incubated
for 1 h with an avidin–biotin–peroxidase complex (ABC kit, PK-6100,
Vector Laboratories) as chromogen and peroxidase activity was visual-
ized using 0.05% 3,30-diaminobenzidine (DAB) and 0.03% H2O2 for
1–2 min. The reaction was stopped by rinsing in KPBS and sections
were mounted onto gelatin-coated slides, dehydrated in ascending
series of ethanol, cleared in xylene and coverslipped using DPX
mounting medium.
For SERT and 5-HT1A receptor immunohistochemistry, sections
containing the SNr were first rinsed in phosphate buffer (PB; 0.1 M,
pH 7.4) and then incubated for 30 min in 30% methanol and 3% H2O2
in 0.1-M PB. After rinsing with PB, sections were placed in 1% sodium
borohydride for 30 min. The sections were profusely washed with PB
before rinsing in Trizma base saline (TS; 0.1 M, pH 7.6) and then incu-
bated in 0.5% BSA and 0.25% Triton (X-100) in TS (TS-T) for 30 min.
Then they were incubated with primary antibody (rabbit anti-SERT,
1:2,500, 24330, Immunostar, Hudson, WI, USA; or rabbit anti-5-HT1A,
1:200, GTX104703, Genetex, California, USA) for 48 h at 22C. Later,
the sections were incubated with the secondary biotinylated antibody
(donkey anti-rabbit IgG, 1:400, 711-005-152, Jackson Immuno-
research, Stratech Scientific; or goat anti-rabbit IgG, BA-1000, 1:200,
Vector Laboratories) in TS-T with 0.5% BSA for 2 h at 22C. Sections
were rinsed in TS followed by incubation for 1 h in avidin–biotin–
peroxidase complex. The reaction was visualized using 0.022% DAB
and 0.003% H2O2 for 10–15 min, as described previously (Aristieta
et al., 2012). The reaction was stopped by rinsing inTS and PB. Finally,
sections were mounted, dehydrated and coverslipped.
2.7.2 | Integrated optical densitometry of the SNr
The integrated optical densitometry (IOD) of tyrosine hydroxylase in
the striatum and SERT and 5-HT1A receptors in the SNr were mea-
sured using NIH-produced software, ImageJ win64 Fiji (https://
imagej.net/Fiji) for reading ODs as grey levels. Digital images from
sections were obtained with the 20× objective of an automatic pano-
ramic digital slide scanner (Pannoramic MIDI II, 3DHistech, Hungary)
using the CaseViewer 2.3 (64-bit version) software. One blinded
investigator performed the integrated optical densitometry reading.
The mean integrated optical densitometry in the SNr was determined
by subtracting the background for each section. Measurements were
performed for two to four sections throughout the SNr and the mean
per animal was calculated. Results (IOD%) were expressed as the per-
centage of optical intensity of the ipsilateral lesioned hemisphere with
respect to the intact or contralateral non-lesioned hemisphere.
2.8 | Drugs
The following drugs were used in this study: urethane,
6-hydroxydopamine hydrobromide, desipramine hydrochloride, pargy-
line, L-DOPA, benserazide hydrochloride and buspirone hydrochlo-
ride, which were obtained from Sigma-Aldrich. WAY-100635 maleate
and 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) were pur-
chased from Tocris-Biogen. Desipramine, pargyline, L-DOPA,
benserazide, buspirone, 8-OH-DPAT and WAY-100635 were pre-
pared in 0.9% saline. Urethane was dissolved in Milli-Q water.
6-OHDA was dissolved in Milli-Q water containing 0.02% ascorbic
acid. All drug solutions were prepared on the day of the experiment.
2.9 | Statistical analysis
The data and statistical analysis comply with the recommendations of
the British Journal of Pharmacology on experimental design and analy-
sis in pharmacology (Curtis et al., 2018). Group size was ≥5, which is
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the number of independent values. Experimental data were analysed
using GraphPad Prism (v. 5.01, GraphPad Software, Inc.). Differences
between experimental groups on basal electrophysiological parame-
ters were analysed using one-way ANOVA except the burst firing
parameters, which were compared using the Fisher's exact test. The
effect of buspirone or 8-OH-DPAT on electrophysiological parame-
ters was matched and analysed by repeated measures (RM) two-way
ANOVA (Lesion × Treatment). As more than one neuron per animal
was recorded when evaluating the effect of locally applied buspirone,
the electrophysiological parameters values were averaged per animal,
so that every animal had one value. In microdialysis, experiments were
expressed as a percentage of the basal value (calculated as the mean
of two samples before treatment). The effect of buspirone on GABA
and glutamate levels in the dialysate was calculated as the summation
changes with respect to the baseline (% basal). Basal values among
groups were compared using one-way ANOVA, whereas the effect of
buspirone was analysed using RM two-way ANOVA. For immuno-
staining results, one-way ANOVA was used. ANOVAs were followed
by Bonferroni's post hoc tests only when it was statistically signifi-
cant, P ≤ 0.05 and there was no significant variance inhomogeneity.
The sphericity of RM two-way ANOVA was assumed by GraphPad
Prism software. The threshold of statistical significance was set at
P < 0.05 with corresponding 95% confidence intervals. Data are pres-
ented as mean ± SEM. All statistical details are described inTable S1.
2.10 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY (Harding et al., 2018) and are permanently
archived in the Concise Guide to PHARMACOLOGY 2019/20
(Alexander et al., 2018).
3 | RESULTS
3.1 | Effect of 5-HT1A drugs on SNr neuronal
activity in anesthetized rats
A total of 92 GABAergic neurons from 54 animals were recorded in
the SNr of anaesthetized rats—31 from the sham group (n = 19 rats),
29 from the 6-OHDA group (n = 17 rats) and 32 from the 6-OHDA/L-
DOPA group (n = 18 rats). All cells recorded were located within the
SNr and displayed the characteristic firing properties described for
SNr-GABAergic neurons in our previous publication (Aristieta
et al., 2016). The mean value of the basal firing rate was higher in the
6-OHDA/L-DOPA group (P < 0.05), the coefficient of variation was
significantly increased in the 6-OHDA/group and the number of bur-
sty neurons was significantly increased in the 6-OHDA and 6-OHDA/
L-DOPA groups. Mean values ± SEM of the firing rate and firing pat-
tern parameters are shown inTable 1.
After recording basal neuronal activity, the experimental groups
were divided into three subgroups to study the effect of 5-HT1A drugs
on SNr neuronal activity. The first subgroup animals from sham,
6-OHDA and 6-OHDA/L-DOPA groups (n = 6, 5, and 5 rats, respec-
tively) received buspirone locally, the second subgroup animals from
control, 6-OHDA and 6-OHDA/L-DOPA groups (n = 8, 7, and 8 rats,
respectively) received buspirone intravenously, and the third subgroup
animals from each group (n = 5 rats each) received 8-OH-DPAT intra-
venously. Thus, the local effect of buspirone was studied on 54 SNr
neurons from a total of 16 animals: 18 neurons from the sham group
(n = 6), 17 neurons from the 6-OHDA group (n = 5) and 19 neurons
from the 6-OHDA/L-DOPA group (n = 5). As it is shown in Figure 2a,
c, local administration of buspirone (0.25–2 nM) caused a marked,
dose-dependent inhibition of neuronal activity in all three experimen-
tal groups, with a maximal reduction of the firing rate of 70% of the
basal value (Figure 2c). No difference in the efficacy of local buspirone
was detected when comparing the percentage effect with respect to
the basal firing values among the groups (Figure 2c). The inhibitory
effect was blocked by previous systemic administration of the 5-HT1A
antagonist WAY-100635 (100 μgkg−1, i.v.) (n = 6 neurons from two
control animals, Figure 2b,d).
Next, the effect of cumulative doses of buspirone (from 0.6125
to 5 mgkg−1, i.v.) on the firing rate and pattern of SNr neurons was
studied in 23 rats (sham n = 8, 6-OHDA n = 7, and 6-OHDA/L-DOPA
n = 8 animals; Figure 3a–c). One neuron per animal was pharmacologi-
cally tested. As shown in Figure 3, systemic administration of








Firing rate (Hz) 20.9 ± 2.0 26.4 ± 2.0 28.4 ± 2.0*
Coefficient of
variation (%)





Number of bursts 13.7 ± 2.7 25.8 ± 8.9 23.9 ± 9.9
Duration of burst (ms) 0.8 ± 0.2 1.2 ± 0.6 1.2 ± 0.7
Spikes/burst 21.3 ± 7.1 31.6 ± 16.6 57.5 ± 31.8
Recurrence of burst (n
burstmin−1)
8.9 ± 1.7 13.2 ± 4.3 14.6 ± 5.9
Intraburst frequency
(spike/s)
49.9 ± 5.7 59.0 ± 6.4 69.1 ± 9.7
Note: Data from the firing rate, coefficient of variation, and percentage of
neurons exhibiting burst firing pattern (of n rats) and burst-related parame-
ters defined as number of bursts, mean duration of the burst, mean num-
ber of spikes per burst, the recurrence of burst per minute, and intraburst
frequency or the interval of spike patterns within bursts. Burst activity
was detected in the spike train in a period of 90 s based following Surprise
method.
*P < 0.05 versus sham (one-way ANOVA followed by Bonferroni's post
hoc test).
$P < 0.05 versus sham (Fisher's exact test).
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buspirone did not modify the firing rate of SNr neurons (Figure 3d)
nor the coefficient of variation (Figure 3e) in any of the groups. How-
ever, systemic buspirone decreased the number of bursty neurons in
the 6-OHDA and 6-OHDA/L-DOPA groups but not in the sham group
(P < 0.05, Fisher's exact test; Figures 3f and S2). No changes in
intraburst parameters were observed. Subsequent intravenous admin-
istration of the 5-HT1A antagonist WAY-100635 (0.5 and 1 mgkg−1)
did not modify either neuron activity or buspirone effect. Table S2
F IGURE 2 Local administration of
buspirone on SNr neuron activity.
Representative firing rate histogram
illustrating the inhibitory local effect of
buspirone on neurons in sham group (a).
Representative firing rate histogram
illustrating the blockage of the inhibitory
local effect of the previous buspirone
administration induced by WAY-100635
(b). Buspirone (0.25–2 nmol) locally
injected into the SNr induced a dose-
dependent inhibitory effect in all three
experimental groups (c). The inhibitory
local effect of buspirone (white circles;
n = 5 neurons from two sham rats) was
blocked by the systemic administration of
WAY-100635 (0.1 mgkg−1, i.v.) (Student's
t-test, P < 0.05) (grey circle; n = 6 neurons
from the same two sham rats) (d). Data
are expressed as mean ± SEM. #P < 0.05
versus respective baseline (RM two-way
ANOVA followed by Bonferroni's post
hoc test) from sham (n = 5), 6-OHDA
(n = 5), and 6-OHDA/L-DOPA (n = 5)
groups
F IGURE 3 Effect of buspirone on SNr neuron activity. Representative firing rate histogram illustrating the lack of effect of buspirone
(0.6125–5 mgkg−1, i.v.) and WAY-100635 (0.5–1 mgkg−1, i.v.) on SNr neuronal firing rate, and schematic representation of burst firing events
that shows the loss of burst firing activity after drug administration in sham (a), 6-OHDA (b), and 6-OHDA/L-DOPA groups (c). Graphical
representation of the mean ± SEM of the firing rate (d), the coefficient of variation (CV), (e) and the number of neurons with burst (f) in the three
experimental groups, sham (n = 8), 6-OHDA (n = 7), and 6-OHDA/L-DOPA (n = 8) before and after increasing doses of buspirone and WAY-
100635. $P < 0.05 versus sham group and &P < 0.05 versus respective baseline (Fisher's exact test for firing pattern)
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summarizes mean ± SEM values of all firing activity parameters before
and after buspirone administration in the three experimental groups.
Finally, we investigated the effect of systemic administration of
8-OH-DPAT (20–160 μgkg−1, i.v.) in 15 animals (sham n = 5,
6-OHDA n = 5 and 6-OHDA/L-DOPA n = 5 animals) (Figure 4a–c).
One neuron per animal was pharmacologically tested. A dose-
dependent inhibition of SNr neuron firing rate was observed in the
sham group, with a maximal reduction of 47% of the basal value
(Figure 4a,d). Conversely, 8-OH-DPAT did not modify the firing rate
of neurons in 6-OHDA and 6-OHDA/L-DOPA groups (Figure 4d).
8-OH-DPAT administration significantly decreased the number of
bursty neurons in all three experimental groups (Figure 4f), without
modifying intraburst parameters (Table S3) or the coefficient of varia-
tion (Figure 4e). WAY-100635 (0.5–1 mgkg−1, i.v.) partially reversed
the effects of 8-OH-DPAT (Figure 4f). Table S3 summarizes
mean ± SEM values of all firing activity parameters before and after
buspirone administration in the three experimental groups.
3.2 | Effect of 5-HT1A drugs on the low oscillatory
activity and synchronization in the SNr and the cortex
Simultaneously with the single-unit recordings of SNr neurons
described above, we also recorded SNr-local field potential and the
electrocorticogram. Later, we analysed the power spectrum and the
coherence in the 0- to 5-Hz range to determine the parameters of
low-frequency activity and synchronization in the SNr and between
this nucleus and the cerebral cortex. In agreement with our previous
results (Aristieta et al., 2016), the analysis showed low oscillatory
activity in the electrocorticogram and the local field potential with a
peak near 1 Hz in all three experimental groups (Figure 5a,b). The
compilation of the AUC values of the electrocorticogram power spec-
trum revealed no significant differences among groups (Figure 5a),
whereas the local field potential AUC value was higher in the
6-OHDA group (Figure 5b). The coherence analysis showed that syn-
chronization between electrocorticogram and SNr spikes and between
local field potential and SNr spikes was higher after 6-OHDA lesion
and L-DOPA treatment, with the AUC value obtained from the coher-
ence curves being significantly larger in the 6-OHDA and 6-OHDA/L-
DOPA groups (P < 0.05; Figure 6a,b). No difference was observed in
the synchronization between electrocorticogram and SNr-local field
potential (Figure 6c).
Next, to investigate the effect of 5-HT1A drugs on low oscillatory
activity and synchronization between SNr and electrocorticogram, we
compared the power spectrum and coherence parameters obtained
before and after the systemic administration of increasing doses of
buspirone or 8-OH-DPAT. Buspirone administration produced a sig-
nificant effect on electrocorticogram (Figure 5c) and local field poten-
tial (Figure 5d), but this effect was only significant for the first
electrocorticogram dose in sham and 6-OHDA groups. On the other
hand, buspirone administration did not affect the synchronization
between electrocorticogram and SNr spikes (Figure 6d). Nevertheless,
buspirone produced a slight but significant effect between local field
potential and SNr spikes (P < 0.05; Figure 6e). Synchronization
between electrocorticogram and local field potential was not affected
much by buspirone (Figure 6f).
Finally, we investigated the effect of systemic 8-OH-DPAT
administration on the oscillatory activity and synchronization. As it is
shown in Figure 5e,f, 8-OH-DPAT did not cause any change in the
AUC of the electrocorticogram and local field potential power spec-
trum. In addition, analysis of coherence revealed that 8-OH-DPAT
had a slight effect on AUC of the coherence between electrocortico-
gram and SNr spikes, but no differences between the three experi-
mental groups were observed (Figure 6g). 8-OH-DPAT did not cause
any effect on the AUC of the coherence between local field potential
and SNr spikes (Figure 6h). In the coherence between electrocortico-
gram and local field potential, there was a significant reduction in
6-OHDA/L-DOPA group with the first dose of 8-OH-DPAT, but no
effects were observed for subsequent doses (Figure 6i).
3.3 | Effect of buspirone on amino acid release in
the SNr from conscious-freely moving rats
We next investigated whether buspirone was able to modulate nigral
GABA and glutamate levels. Immediately before buspirone perfusion,
basal GABA and glutamate levels in the dialysate from the probe
implanted in the SNr did not differ among the three experimental
groups 7.28 ± 2.65 nM and 94.35 ± 11.99 nM, respectively, in naïve
animals (n = 11), 8.44 ± 1.89 nM and 110.27 ± 16.01, respectively, in
6-OHDA animals (n = 11), and 8.73 ± 1.58 and 71.87 ± 7.65, respec-
tively, in 6-OHDA L-DOPA animals (n = 8). Local perfusion of
buspirone (50, 150 and 500 nM) raised dialysate GABA levels in naïve
and 6-OHDA groups but had no effect in 6-OHDA/L-DOPA animals
(Figure 7a). However, the GABA enhancement was significantly lower
in the 6-OHDA group when compared to that in the naïve group
(Figure 7b,c). Likewise, buspirone also elevated dialysate glutamate
release in naïve and 6-OHDA groups, but it had no effect in
6-OHDA/L-DOPA animals (Figure 7d–f). Again, the effect of
buspirone on 6-OHDA-lesioned rats was significantly less when com-
pared to the effect on naïve rats (Figure 7d,e,f).
3.4 | SERT and 5-HT1A immunostaining in the SNr
Published studies concerning 5-HT innervations and 5-HT1A receptors
in the basal ganglia after 6-OHDA lesion have shown uniform results
(see Miguelez, Morera-Herreras, Torrecilla, Ruiz-Ortega, &
Ugedo, 2014). Therefore, in order to investigate the mechanism
involved in the observed changes produced by buspirone after
6-OHDA lesion, we evaluated SERT and 5-HT1A immunoreactivity
expression in the SNr of animals in the three experimental groups
(sham n = 5, 6-OHDA n = 5 and 6-OHDA/L-DOPA n = 5 animals). The
overall integrated optical densitometry for SERT or 5-HT1A immuno-
reactivity was unchanged by the 6-OHDA lesion. By contrast,
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prolonged L-DOPA treatment significantly increased SERT (Figure 8c)
and significantly decreased 5-HT1A receptor expression (Figure 8d).
4 | DISCUSSION
We have used 6-OHDA-lesioned rats, a well-characterized experi-
mental model of Parkinson's disease, to elucidate whether the sub-
stantia nigra pars reticulata (SNr) could be a good target to evaluate
pharmacological treatments for the motor symptoms associated with
Parkinsonism. Buspirone is one of the most effective drugs in reduc-
ing motor symptoms and it can reverse certain molecular changes
induced by L-DOPA in parkinsonian rats (Azkona et al., 2014;
Dekundy et al., 2007; Eskow, Gupta, Alam, Park, & Bishop, 2007).
Here, we show that in anaesthetized rats buspirone (1) reduces the
firing rate of SNr neurons when administered directly to the nucleus,
(2) decreases bursty activity when it is applied systemically after DA
loss but not in control conditions and (3) has no effect on local field
potential and synchronization between the cortex and the SNr and
within the nucleus. In addition, buspirone modulates GABA and
glutamate levels depending on the integrity of DA pathways. Thus,
amino acid levels were increased in control conditions, were little
affected after DA degeneration and were not modified after 6-OHDA
lesion and L-DOPA treatment.
4.1 | Effect of buspirone on SNr neuron activity
Although numerous behavioural studies have shown the efficacy of
full or partial 5-HT1A receptor agonists in decreasing dyskinesias, no
study has examined how these drugs may affect the altered output
basal ganglia activity in Parkinson's disease and l-DOPA-induced dys-
kinesia. Here, we first show that the firing rate of SNr neurons was
reduced when buspirone was administered directly into the nucleus.
However, buspirone caused no change in the firing rate of SNr neu-
rons when administered systemically, whereas 8-OH-DPAT dose-
dependently reduced it. The effects of local as well as systemic 8-OH-
DPAT can be attributed to 5-HT1A receptor activation since they were
antagonized by WAY-100635. Altogether, these results indicate that
the reduction of firing rate involves 5-HT1A receptors located within
F IGURE 4 Effect of 8-OH-DPAT on SNr neuron activity. Representative firing rate histogram illustrating the absence of effects of 8-OH-
DPAT (20–160 μgkg−1, i.v.) and WAY-100635 (0.5–1 mgkg−1, i.v.) on SNr neuronal firing rate, and schematic representation of burst firing
events that shows the loss of burst firing activity after drug administration in sham (a), 6-OHDA (b), and 6-OHDA/L-DOPA groups (c). Graphical
representation of the mean ± SEM of the firing rate (d), the coefficient of variation (CV). (e) and the number of neurons with burst (f) in the three
experimental groups, sham (n = 5), 6-OHDA (n = 5), and 6-OHDA/L-DOPA (n = 5) before and after increasing doses of 8-OH-DPAT and WAY-
100635. Data are expressed as mean ± SEM. *P < 0.05 versus sham group (RM two-way ANOVA followed by Bonferroni's post hoc test), and
&P < 0.05 versus corresponding basal value (Fisher's exact test for firing pattern)
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the SNr and 5-HT1A receptors located on excitatory and inhibitory
neurons that project to the SNr. Thus, the systemic effects of
buspirone and 8-OH-DPAT depend first on the inhibition of 5-HT
neurons in the raphe nuclei and the activity modulation of the stria-
tum, globus pallidus and the subthalamic nucleus and second on the
direct activation of 5-HT1A receptors in the SNr. In fact, the dorsal
raphé nucleus sends efferentes to the SNr (Moukhles et al., 1997) as
well as to the other basal nuclei (see Di Matteo et al., 2008).
Differences between the effects of buspirone and 8-OH-DPAT
likely rely on the fact that 8-OH-DPAT is a full agonist at presynaptic
and postsynaptic 5-HT1A receptors (which results in inhibition of the
spontaneous firing rate of 5-HT neurons and 5-HT release) and
reduces inhibitory responses on targeted structures (Blier, Lista, & De
Montigny, 1993; Martín-Ruiz & Ugedo, 2001; Sprouse &
Aghajanian, 1988). Conversely, buspirone acts as a full agonist at pre-
synaptic 5-HT1A receptors inhibiting 5-HT neurons (VanderMaelen,
Matheson, Wilderman, & Patterson, 1986) but as a partial agonist of
postsynaptic 5-HT1A receptors (Cowen, Power, Ware, &
Anderson, 1994; Eison & Temple, 1986), where its effect will depend
on 5-HT levels at the synaptic cleft. Notably, following DA depletion
and L-DOPA treatment, the effect of 8-OH-DPAT was abolished. In
that sense, several studies have shown that dysfunction of 5-HT1A
receptors in rats after DA degeneration decreases or abolishes the
effect of 8-OH-DPAT on GABAergic interneurons (Hou et al., 2012)
and pyramidal neurons (Wang, Zhang, Liu, Wu, Ali, et al., 2009a).
However, regarding the effect of systemic 8-OH-DPAT administration
on dorsal raphé nucleus neurons, a loss in efficacy of inhibition
(Wang, Zhang, Liu, Wu, Wang, et al, 2009b) or no changes (Miguelez,
Navailles, De Deurwaerdère, & Ugedo, 2016) have been reported.
Interestingly, systemic administration of buspirone reduced the num-
ber of bursty SNr neurons after DA loss but not in control conditions
where 8-OH-DPAT has a more pronounced effect. Precisely, an incre-
ment in burst activity was the major change we observed in the SNr
neurons from the 6-OHDA and 6-OHDA/L-DOPA groups, which is
F IGURE 5 Effect of buspirone on
low oscillatory activity and
synchronization of SNr neurons and
electrocorticogram (ECoG) of the motor
cortex. Power spectra (0- to 5-Hz
frequency range) and AUC values
obtained from the ECoG (a) and SNr-local
field potential (LFP) (b) in the sham
(n = 19), 6-OHDA (n = 17), and 6-OHDA/
L-DOPA (n = 18) animals. Effect of
administration of increasing doses of
buspirone (0.6125–5 mgkg−1, i.v.) on the
AUC of the power spectrum of the ECoG
(c) and SNr-LFP (d) in the sham (n = 8),
6-OHDA (n = 7), and 6-OHDA/L-DOPA
(n = 8) animals. Effect of administration of
increasing doses of 8-OH-DPAT
(20–160 μgkg−1, i.v.) on the AUC of the
power spectrum of the ECoG (e) and SNr-
LFP (f) obtained from the three
experimental groups, sham (n = 5),
6-OHDA (n = 5), and 6-OHDA/L-DOPA
(n = 5). Data are expressed as
mean ± SEM. @P < 0.05 versus sham
(one-way ANOVA followed by
Bonferroni's post hoc test) and #P < 0.05
versus respective baseline (RM two-way
ANOVA followed by Bonferroni's post
hoc test)
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also in line with data from electrophysiological studies in
anaesthetized rats, which have reported changes in firing patterns
rather than in the firing frequency (Aristieta et al., 2016; Meissner
et al., 2006; Tseng et al., 2000). This enhancement in burst activity
may be due to changes in synaptic plasticity induced by DA loss (see
Lobb, 2014). It seems that bursting activity is more relevant in
information-carrying signals (Chergui, Nomikos, Mathé, Gonon, &
Svensson, 1996) and neurotransmitter release rather than single
action potentials (Gonon, 1988). Therefore, the decrement in burst
activity induced by buspirone will produce less intense GABA releases
in agreement with our microdialysis results discussed below.
4.2 | Effect of buspirone on SNr neuron oscillatory
activity and synchronization
Cortical slow-wave activity induced by urethane anaesthesia favours
low-frequency oscillations in the cortex and the basal ganglia nuclei in
rats, including the SNr (Aristieta et al., 2016; Brown, 2006; Clement
et al., 2008; Magill, Bolam, & Bevan, 2001). Thus, the later cited stud-
ies demonstrated that these electrophysiological properties are
altered in 6-OHDA-lesioned and L-DOPA-treated rats, which show
that coupling between the cortex and the SNr increased. In agreement
with these findings, we also observed oscillatory activity in the low-
F IGURE 6 Synchronization between the SNr and electrocorticogram (ECoG) of the motor cortex in low-frequency range (0.5–5 Hz) was
higher in 6-OHDA-lesioned groups. Coherence power between the ECoG and SNr spikes simultaneously recorded in the sham (n = 19), 6-OHDA
(n = 17), and 6-OHDA/L-DOPA (n = 18) groups. AUC value obtained from coherence between the ECoG and SNr spikes was augmented in
6-OHDA L-DOPA group (a). AUC values obtained from SNr-local field potential (LFP)/SNr spikes coherence curves showed an increase in
6-OHDA L-DOPA group (b). AUC values obtained from ECoG/SNr-LFP coherence curves showed no differences (c). Effect of administration of
acute doses of buspirone (0.6125–5 mgkg−1, i.v.) on the synchronization between ECoG and SNr spikes (d), between SNr-LFP and SNr spikes (e),
and between ECoG and SNr-LFP (f) in the sham (n = 8), 6-OHDA (n = 7), and 6-OHDA/L-DOPA (n = 8) groups. Effect of administration of acute
doses of 8-OH-DPAT (20–160 μgkg−1, i.v.) on the synchronization between ECoG and SNr spikes (g), between SNr-LFP and SNr spikes (h), and
between ECoG and SNr-LFP (i) in the sham (n = 5), 6-OHDA (n = 5), and 6-OHDA L-DOPA (n = 5) groups. Data are expressed as mean ± SEM.
@P < 0.05 versus sham (one-way ANOVA followed by Bonferroni's post hoc test), *P < 0.05 versus sham, and #P < 0.05 versus respective baseline
(RM two-way ANOVA followed by Bonferroni's post hoc test)
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frequency band (0–5 Hz) in the cortex and the SNr, and an increased
synchronization between them after DA loss and L-DOPA treatment.
This low-frequency oscillatory activity and synchronization were not
affected by systemic buspirone or 8-OH-DPAT administration at the
same doses that modified bursty activity. So far, there are no studies
regarding the effect of antidyskinetic drugs on this low oscillatory
activity, but our previous work found that an acute L-DOPA challenge
had little effect on it (Aristieta et al., 2016). It seems, therefore, that
while low-frequency oscillatory activity and synchronization do not
have a relevant role in l-DOPA-induced dyskinesia, they may be
important in Parkinson's disease. In fact, recent published evidence
obtained from 6-OHDA-lesioned rats indicates that oscillations in dis-
tinct spectral bands are differently affected at every Parkinsonism
stage and may be differently modulated by pharmacological treat-
ments. Thus, recordings in awake animals have shown that, apart from
decreasing dyskinesia, 5-HT-antidyskinetic drugs suppressed 80-Hz
oscillation activity but not the oscillations in other bands (5–10 Hz
and 110–140 Hz) (Brys et al., 2018). Similarly, oscillations in the β
band (24–36 Hz) were elevated, but those in the θ band (5–8 Hz)
were unchanged after the 6-OHDA lesion. However, θ activity was
elevated and correlated with abnormal involuntary movements score
in 6-OHDA-lesioned rats treated with L-DOPA and was reduced by
eltoprazine, a 5HT1A/B agonist (Wang et al., 2019).
4.3 | Effect of buspirone on SNr neuron amino acid
levels
In this study, using microdialysis approaches we found no significant
changes in GABA and glutamate basal levels after DA loss with or
without prolonged L-DOPA treatment. This finding is consistent with
those of other studies performed in freely moving 6-OHDA-lesioned
rats (Bianchi et al., 2003; Mela et al., 2007). However, we found that
the enhancement in GABA and glutamate release induced by locally
perfused buspirone in control animals was significantly reduced after
6-OHDA lesion and almost abolished after prolonged L-DOPA treat-
ment. The sources of GABA in the SNr include the striatal and globus
pallidus terminals, and collaterals of GABAergic neurons of the SNr,
while the subthalamic nucleus provides the major glutamatergic input
to the SNr (Kita & Kitai, 1987). In control conditions, GABA and gluta-
mate release in the SNr may be regulated by 5-HT1A receptors local-
ized on 5-HT terminals coming from the raphé nuclei, striatal, globus
pallidus and subthalamic terminals and nigral GABAergic neurons. The
fact that the inhibitory effect of buspirone on SNr neuron activity was
unchanged after 6-OHDA lesion rules out the possibility that changes
in 5-HT1A receptors on GABAergic neurons are responsible for the
reduction of GABA released. However, this may reflect altered
responsiveness from afferent terminals as shown for nigral GABA
F IGURE 7 Effect of local perfusion of buspirone (50–500 nM) on nigral amino acid levels of GABA (a–c) and glutamate (Glu) (d–f). Local
perfusion of buspirone raised nigral GABA levels in naïve (n = 9) and 6-OHDA (n = 11) groups, but with less intensity, and it had no effect in
6-OHDA/L-DOPA (n = 7) group (a). Buspirone also raised nigral Glu levels in naïve (n = 10) and 6-OHDA (n = 9) groups, with less intensity, and it
had no effect in 6-OHDA/L-DOPA (n = 7) group (d). Bar representation (mean ± SEM) of the AUC (60–240 min) (b and e) and AUC 60 min after
administration of the respective buspirone concentration dose (c and f). Data are expressed as percentage of basal levels calculated as the mean
of the two samples preceding buspirone perfusion. *P < 0.05 versus naïve group and xP < 0.05 versus respective dose of 6-OHDA group
(RM two-way ANOVA followed by Bonferroni's post hoc test)
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release following striatal kainate application and for glutamate release
following local application of K+ in 6-OHDA-lesioned rats (Bianchi
et al., 2003). Furthermore, buspirone, besides being a 5-HT1A partial
agonist also has D2 and D3/D4 receptor antagonist activity (Bergman
et al., 2013). These receptors, whose activity is modulated by the
6-OHDA lesion (Avalos-Fuentes et al., 2013), are present in the
pallidonigral and striatonigral terminals, modulate GABA release
(Acosta-García et al., 2009; Avalos-Fuentes et al., 2015) and are
involved in the antidyskinetic effect of buspirone (Azkona et al., 2014;
Shin et al., 2014). Therefore, changes in GABA and glutamate release
induced by buspirone may involve modulation of several receptors
apart from 5-HT1A receptor. In fact, in the present study, we only
found a decrease in optical density of 5-HT1A receptors in the SNr
from 6-OHDA-lesioned rats with prolonged L-DOPA treatment where
buspirone effect on amino acid release was negligible. However, no
changes were observed after DA degeneration, while buspirone effect
was reduced compared to that in control conditions.
4.4 | SERT and 5-HT1A receptor expression in the
SNr from 6-OHDA-lesioned rats
Published studies regarding SERT and 5-HT1A receptor changes in
Parkinson's disease have provided contradictory results showing
increased, decreased or unmodified expression of these proteins both
in humans and in animal models. This discrepancy may be due to the
stage of the disease, the treatment, or the experimental model used
(for review, see Vegas-Suarez et al., 2019). To better explain our elec-
trophysiological and microdialysis results, we performed immunohis-
tochemical detection of SERT and 5-HT1A in the same experimental
model. Results show that SNr expression of SERT is increased and this
observation agrees with the findings of a study involving the striatum
of hemiparkinsonian rats (Rylander et al., 2010). The 5-HT1A receptor
density was decreased in that case in disagreement with published
results showing no striatal changes (Riahi et al., 2012). However,
although in both cases the change is significant, it is only around a
F IGURE 8 Coronal sections
immunoassayed for SERT axon
terminals (a) and 5-HT1A receptors
(b) of the SNr. Micrographs at 20×
magnifications for the three
experimental groups. In the top of the
figure, a representative brain coronal
section of the SNr (Nissl staining) with
delimited sections from ipsilateral
(IP) and contralateral
(CL) hemispheres. Scale bar = 50 μm.
While the IOD of SERT terminals
left/right ratio shows a significant
increase in SERT terminals (c), 5-HT1A
receptor left/right ratio shows a
significant decrease in 6-OHDA/L-
DOPA group (d). Sham (n = 5),
6-OHDA-lesioned (n = 5), and
6-OHDA/L-DOPA (n = 5). Each bar
represents the mean ± SEM. *P < 0.05
versus sham (one-way ANOVA
followed by Bonferroni's post hoc
test)
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10% of the control value and was only present in 6-OHDA-lesioned
animals that had undergone prolonged treatment of L-DOPA. It could
be speculated that changes in 5-HT1A receptors take place on termi-
nals rather than on SNr neurons, which could explain why local
buspirone administration has no effect. On the other hand, these
results could help to understand the lack of the effect of buspirone on
amino acid release in 6-OHDA-lesioned and prolonged L-DOPA-
treated animals but not the decreased effect of buspirone on
6-OHDA-lesioned rats. Therefore, it is hard to consider that changes
in density are responsible of the altered response to buspirone
observed after 6-OHDA lesion and complex mechanisms underlying
the decreasing receptor sensitivity are probably involved.
4.5 | Experimental considerations
This study was performed only in male rats to avoid gender influence
in the results, since electrophysiological differences between male
and female have been observed in Parkinson's disease patients (see
review Picillo et al., 2017). In this regard, recordings in the STN have
shown sex-related differences in spike parameters and high-γ band
oscillations activity (Marceglia et al., 2006; Mrakic-Sposta
et al., 2008). The development of l-DOPA-induced dyskinesia and the
response to deep brain stimulation also differ between female and
male subjects (Accolla et al., 2007; Hassin-Baer et al., 2011). In this
line, previous work from our laboratory confirmed gender differences
in the STN neurons from 6-OHDA-lesioned rats with and without L-
DOPA prolonged treatment (Sagarduy et al., 2016). A limitation of the
present study is that recordings were performed in anaesthetized ani-
mals, and it may be argued that this does not accurately represent
clinical situations. However, we have recently characterized the elec-
trophysiological parameters in this model of DA loss and demon-
strated a relationship between the observation of abnormal
involuntary movements and recording parameters under anaesthesia.
Thus, we chose to use buspirone in this study because we knew from
previous studies that a single dose of buspirone applied before L-
DOPA was able to reduce abnormal involuntary movements and cer-
tain molecular changes observed in 6-OHDA-lesioned and L-DOPA-
treated rats (Azkona et al., 2014; Sagarduy et al., 2016).
5 | CONCLUSION
The relevance of the SNr in Parkinson's disease and L-DOPA-induced
dyskinesia is evidenced by aberrant changes of nigral neuron activity
observed after DA depletion and L-DOPA treatment in animal models,
as well as the symptomatic efficacy of therapeutic interventions that
normalize nigral activity in both animal models and patients with
Parkinson's disease. Our results show that buspirone modulates amino
acid release and neuronal activity, mainly burst activity, in the SNr of
the rat. However, these effects are modulated by DA loss and long-
term L-DOPA treatment. These novel findings indicate that the regula-
tion of burst activity in the SNr induced by DA loss may be a good
target to test new drugs for the treatments of Parkinson's disease and
dyskinetic patients and point out the importance of using experimen-
tal models of Parkinson's disease and L-DOPA-induced dyskinesia
when investigating the potential therapeutic effect of new drugs.
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